AJSM publishes first peptide therapy primer for sports medicine
USC researchers publish an AJSM primer on injectable peptide therapy, covering BPC-157, TB-500, GH secretagogues, and GHK-Cu with formal evidence grades.
May 9, 2026 · 3 min read
Researchers from the Keck School of Medicine at USC published the first dedicated primer on injectable peptide therapy for sports medicine clinicians in the January 2026 issue of the American Journal of Sports Medicine. The paper by Cory K. Mayfield, Ioanna K. Bolia, and colleagues provides an evidence-graded review of BPC-157, TB-500, CJC-1295 combined with Ipamorelin, Tesamorelin, and GHK-Cu — the compounds their patients are already asking about in orthopaedic and sports medicine practice.
What happened
The paper appears in AJSM 54(1):223-229 and is authored by Mayfield, Bolia, Cailan L. Feingold, Eric H. Lin, Joseph N. Liu, George F. Rick Hatch, Seth C. Gamradt, and Alexander E. Weber, all affiliated with USC's Keck School of Medicine in Los Angeles. Its stated purpose is practical: to give clinicians a factual foundation for responding to patient questions about compounds that are already in widespread use despite lacking FDA approval.
On BPC-157, the review found evidence in preclinical models for tendon and muscle repair but concluded that human data remain largely absent. TB-500 and its derivative fragment TB-4 showed angiogenesis and tissue repair activity in preclinical settings; the review noted both are prohibited by the World Anti-Doping Agency, making them relevant not only as potential therapeutics but as banned substances in competitive sport. The CJC-1295 and Ipamorelin combination showed significantly improved muscle contractile force in glucocorticoid-challenged murine models; the authors rated the human translation evidence as limited. GHK-Cu, a copper-binding tripeptide, received attention for preclinical anti-inflammatory and wound-healing data.
The paper joins a growing body of sports medicine literature addressing the peptide question head-on. A separate 2025 systematic review by Vasireddi et al. in Sports Health examined 36 preclinical and clinical studies of BPC-157 in orthopaedic applications specifically, and a narrative review by McGuire et al. in Current Reviews in Musculoskeletal Medicine (December 2025) reached similar conclusions on the gap between animal evidence and human data.
Why it matters
An evidence review in the American Journal of Sports Medicine is not just an academic exercise. AJSM is the flagship publication of the American Orthopaedic Society for Sports Medicine and is read by the orthopedic surgeons, team physicians, and sports medicine doctors who are often the first point of contact for athletes using or asking about peptides. A primer in that journal signals that the specialty is taking the topic seriously rather than dismissing it.
The practical consequence is that more sports medicine physicians will now have a structured framework for advising patients, rather than either refusing engagement or giving anecdotal guidance. The review's conservatism — it recommends against recommending any of the covered compounds for clinical use outside formal trials — is itself useful: it sets a defensible institutional baseline at a moment when regulatory access may be expanding.
This matters for peptide users directly. Broader physician literacy on compounds like BPC-157 and TB-500, even cautious literacy, creates pressure for the clinical trials that would ultimately establish approved indications. It also means patients are more likely to encounter practitioners who know what BPC-157 is rather than practitioners who must start from zero when a patient discloses use.
What to watch
- Whether the AJSM primer generates follow-on research submissions — editorials, letters, or trial proposals — that cite it as a foundation
- Any U.S. sports medicine society position statement on peptide use that draws on this or similar reviews
- Trial registration activity on ClinicalTrials.gov for any of the covered compounds — the primer notes the absence of registered human trials as a key gap
- Publication of the broader injectable peptide landscape in other high-impact journals (JBJS, CORR) as the sports medicine community reaches consensus
Sources
Sources